



## Guidelines for Abstract Submission

### General

Below are the guidelines for your abstract submission. Details are included in the form. Please ensure that your abstract submission follows these requirements.

Please make a note of the email and password you used to create your submission. If your submission is partial or you wish to revise before the deadline, you will need to use the login you created. Individuals may submit up to two abstracts as primary or presenting author.

### Deadline for Submissions

**Deadline for submission: May 8, 2023**

Late breaking abstracts should also be submitted as a shell application by **May 8, 2023** with final application including final data submitted by **July 1, 2023**. Applications will be reviewed and selected for presentation by the Abstract Committee.

Notifications will be sent by **June 9, 2023**, and for Late Breaking Abstracts by **July 1, 2023**.

### General Requirements

- Type the text unjustified without hyphenating words at line breaks.
- Use single line spacing. Use hard returns only to end headings and paragraphs.
- Abbreviations should be used as sparingly as possible and should be defined when first used.
- All abstracts must be in English. Spelling within any one abstract should be US English or UK English, but not a mixture.
- In most cases, Greek letters and other special characters will transfer from your word processing software via copy and paste functions. If you are unable to reproduce a particular special character, type out the name of the symbol in full.
- SI units should be used throughout (liter and molar are permitted, however.)

### Title

The title must be entered exactly as it should appear and should be in sentence case. Do not put the title in quotes, underline it, or use punctuation. The title can be a maximum of 200 characters, including spaces.

### Research Topic Category

All abstract submitters will be asked to indicate the primary category with which the abstract most closely aligns.

Kidney Cancer Research Summit 2023 will accept submissions in the following categories:

- Basic/Translational Research
- Trials in Progress/Clinical Research

Abstracts accepted for oral presentation do not require a corresponding poster. All presentations are live in Boston to ensure that presenters are active in the session discussions.

For KCRS23 we are not able to accept poster presentations.

Abstract submissions with original data are preferred. One oral presentation slot is reserved for a significant encore presentation. You have until the deadline on **May 8, 2023** to submit your encore abstract.

Submissions with late-breaking clinical data require a shell submission by **May 8, 2023**. The full submission for late-breaking abstracts is due **July 1, 2023**.

### Abstract Structure

The following is included in the abstract body and must not exceed 600 words total:

Background  
Methods  
Results\*  
Conclusions\*

*\*For Clinical Trials in Progress, results and conclusions are not required.*

One table, graph, or illustration is allowed and not included in the word count.

### Keywords

All abstract submitters will be asked to indicate keywords for their abstract.

## Authors and Institutions

All authors and contact information must be listed in the correct order. The order in which authors will be listed in the author block of all publications is the order that they are entered.

Each author **MUST** indicate at least one institution affiliation. Affiliations should include Department, University, Town, State, USA OR Institution, Town, Country, for example.

There is no limit to the number of authors you can include.

Your submission needs to have a minimum of: one Corresponding Author, one Presenting Author, one Primary Author. These three roles may be fulfilled by the same individual. Each presenting author may submit no more than two abstracts.

The presenting author will need to submit Conflicts of Interest online. Usually a standard COI summary or a statement “No Relevant COI’s” will suffice but other information may be added to the submission form as needed.

The presenting author submitting an abstract must agree to the following:

- Serve as the contact for all correspondence about the abstract and inform co-authors about its status
- Confirm all authors are aware of and agree to the content and data presented in the abstract
- Verify the abstract is accurate and that permission has been obtained from all relevant parties
- Verify the abstract has not been published prior to KCRS23 or if previously published, contains significant new data
- If this is Encore Clinical Data, indicate “Encore Presentation” in the Presentation Type question
- Agree to follow all media and press release policies set forth by KidneyCAN

## Trial Registration

If applicable, abstracts related to clinical trials (RCTs) should include the trial registry along with the unique identifying number.

**The data in the abstract must not be published prior to KCRS23.**

## Late-Breaking Abstracts

Late-breaking abstract applications will need to indicate if it is a clinical or lab-based study and will need to include the following information in their application:

- Clinical Study
- Closure date of the study
- Primary clinical endpoint for analysis
- Type of analysis

### Late-Breaking Abstract Information and Eligibility

Late-breaking abstract submission is solely for abstracts with late-breaking data and not for abstracts submitted “late.” The late-breaking abstract deadline is not intended to be an extension of the general submission deadline. Late-breaking abstracts highlight novel and practice-changing studies, and only apply to data that would have not otherwise have been presented as an abstract at KCRS23.

Examples of acceptable late-breaking abstracts include the following (in each case, results were not available or significant by the regular abstract submission deadline):

- Results of a practice-changing prospective Phase III clinical trial
- Phase II study showing anti-tumor activity in a novel context
- An early clinical trial with novel proof-of-principle data

Authors need to justify late consideration by documenting the reason for late breaking data.

A shell abstract must be submitted by May 8, 2023, and submit a late-breaking abstract application by July 1, 2023. This application needs to include necessary abstract information (without results and conclusions) and incorporate the primary clinical endpoint for analysis, type of analysis, date of planned analysis, and planned statistical methods for analysis.

## Contact

For further information please contact: [Susan.Poteat@KidneyCAN.org](mailto:Susan.Poteat@KidneyCAN.org)